Search results for " effect"

showing 10 items of 7524 documents

Hemodynamic Effects of Ventricular Pacing

1985

Fixed rate ventricular pacing is used in most cases of implanted pacemakers. It does not usually create considerable hemodynamic problems, as the heart, by its adaptation mechanism, is capable of varying its pump performance to meet the metabolic needs[1,3].

medicine.medical_specialtyEjection fractionbusiness.industryInternal medicineStrenuous exerciseModerate exerciseCardiologyMedicineHemodynamicsStroke volumeVentricular pacingbusinessHemodynamic effects
researchProduct

2015

Neuropsychological group study methodology is considered one of the primary methods to further understanding of the organisation of frontal ‘executive’ functions. Typically, patients with frontal lesions caused by stroke or tumours have been grouped together to obtain sufficient power. However, it has been debated whether it is methodologically appropriate to group together patients with neurological lesions of different aetiologies. Despite this debate, very few studies have directly compared the performance of patients with different neurological aetiologies on neuropsychological measures. The few that did included patients with both anterior and posterior lesions. We present the first co…

medicine.medical_specialtyElementary cognitive taskCognitive NeuroscienceTrail Making TestNeuropsychologyExperimental and Cognitive PsychologyAudiologyExecutive functionsbehavioral disciplines and activitiesLesionBehavioral NeuroscienceFrontal lobemedicineEffects of sleep deprivation on cognitive performancemedicine.symptomPsychologyPsychiatryStroop effectNeuropsychologia
researchProduct

Relationships of “ambulatory” white coat effect with target organ damage in arterial hypertension

2001

medicine.medical_specialtyEnd organ damagebusiness.industryDiastolemedicine.diseaseBlood pressureHypertensive retinopathyInternal medicineAmbulatoryInternal MedicinemedicineCardiologyMicroalbuminuriaSystolebusinessWhite coat effectAmerican Journal of Hypertension
researchProduct

A 15-Year Perspective of the Fabry Outcome Survey

2016

Abstract The Fabry Outcome Survey (FOS) is an international long-term observational registry sponsored by Shire for patients diagnosed with Fabry disease who are receiving or are candidates for therapy with agalsidase alfa (agalα). Established in 2001, FOS provides long-term data on agalα safety/efficacy and collects data on the natural history of Fabry disease, with the aim of improving clinical management. The FOS publications have helped establish prognostic and severity scores, defined the incidence of specific disease variants and implications for clinical management, described clinical manifestations in special populations, confirmed the high prevalence of cardiac morbidity, and demon…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030204 cardiovascular system & hematologyoutcomesFabry Outcome Survey03 medical and health sciences0302 clinical medicineInternal medicinemedicineGenetics (clinical)lcsh:R5-920agalsidase alfaFabry diseasebusiness.industryIncidence (epidemiology)Therapeutic effectEnzyme replacement therapymedicine.diseaseFabry diseaseNatural historyPediatrics Perinatology and Child HealthPhysical therapyObservational studybusinesslcsh:Medicine (General)Agalsidase alfa030217 neurology & neurosurgeryenzyme replacement therapy
researchProduct

Developmental programming of energy balance and its hypothalamic regulation.

2011

Developmental programming is an important physiological process that allows different phenotypes to originate from a single genotype. Through plasticity in early life, the developing organism can adopt a phenotype (within the limits of its genetic background) that is best suited to its expected environment. In humans, together with the relative irreversibility of the phenomenon, the low predictive value of the fetal environment for later conditions in affluent countries makes it a potential contributor to the obesity epidemic of recent decades. Here, we review the current evidence for developmental programming of energy balance. For a proper understanding of the subject, knowledge about ene…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismEnergy balanceHypothalamusBiologyPredictive valueRatsFetal DevelopmentMiceEndocrinologyEndocrinologyRisk analysis (engineering)PregnancyInternal medicinePrenatal Exposure Delayed EffectsModels AnimalmedicineAnimalsHumansFemaleEnergy MetabolismDevelopmental programmingOrganismSignal TransductionEndocrine reviews
researchProduct

Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies

2019

Background: Age, smoking, hypercholesterolemia, and hypertension are major risk factors for atherosclerotic cardiovascular disease. Objective: We examined whether the effects of alirocumab on low-density lipoprotein cholesterol (LDL-C) differed according to age, hypertension, or smoking status. Methods: Data were pooled from 10 Phase 3 ODYSSEY randomized trials (24–104 weeks’ duration) in 4983 people with heterozygous familial hypercholesterolemia (FH) or non–familial hypercholesterolemia (3188 on alirocumab, 1795 on control [620 on ezetimibe and 1175 on placebo]). Most participants received concomitant maximum tolerated statin therapy. In 8 trials, the alirocumab dose was increased from 75…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedPlacebolaw.inventionPCSK903 medical and health sciencesAge0302 clinical medicineRandomized controlled trialEzetimibeRisk FactorslawInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineAdverse effectAgedAlirocumabNutrition and Dieteticsbusiness.industryPCSK9SmokingAge FactorsCholesterol LDLMiddle Agedmedicine.diseaseCholesterolTreatment OutcomeConcomitantHypertensionCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Clinical Lipidology
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct

Die Hemmung der Noradrenalin-Abgabe durch Acetylcholin am sympathisch gereizten, isolierten Kaninchenherzen / The Inhibitory Effect of Acetylcholine …

1969

Nicotinartig wirkende Substanzen setzen aus chromaffinen Zellen und aus sympathischen Nervenendigungen Noradrenalin (NA) frei. Am isolierten Saugetierherzen wird diese NA-Freisetzung aber gehemmt, wenn gleichzeitig Muscarinreceptoren z. B. durch Acetylcholin (ACh) oder Methacholin erregt werden (Lindmau Loffelholz u. Muscholl

medicine.medical_specialtyEndocrinologyChemistryInternal medicinemedicineInhibitory effectAcetylcholinemedicine.drug
researchProduct

The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract

2010

Aliment Pharmacol Ther 31, 548–552 Summary Background  Confocal laser endomicroscopy (CLE) is rapidly emerging as a valuable tool for gastrointestinal endoscopic imaging. Fluorescent contrast agents are used to optimize imaging with CLE, and intravenous fluorescein is the most widely used contrast agent. Fluorescein is FDA-cleared for diagnostic angiography of the retina. For these indications, the safety profile of fluorescein has been well-documented; however, to date, fluorescein is not cleared for use with CLE. Aims  To estimate the rate of serious and total adverse events attributable to intravenous fluorescein when used for gastrointestinal CLE. Methods  We performed a cross sectional…

medicine.medical_specialtyErythemaNauseaGastrointestinal DiseasesVomitingContrast MediaPainEndoscopy Gastrointestinalchemistry.chemical_compoundmedicineHumansPharmacology (medical)FluoresceinAdverse effectGastrointestinal tractMicroscopy ConfocalHepatologymedicine.diagnostic_testbusiness.industryUnited States Food and Drug AdministrationStomachfungiGastroenterologyNauseaExanthemaUnited StatesSurgeryEndoscopymedicine.anatomical_structureCross-Sectional StudieschemistryAnesthesiaInjections IntravenousVomitingFluoresceinmedicine.symptomHypotensionbusinessAlimentary pharmacology & therapeutics
researchProduct

Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of severe nasolabial lines - 6-month interim results of a randomized, eva…

2011

Summary Background  Hyaluronic acid (HA) fillers are frequently used for the correction of facial soft tissue defects. Aim  To compare the efficacy and safety of a novel HA filler, HAE (Emervel Deep), with those of HAP (Restylane Perlane) in the treatment of severe nasolabial folds (NLF). Patients/Methods  A split-face, randomized and evaluator-blinded comparison study. Subjects were randomized to receive injection of HAE or HAP on their left or right NLF. Efficacy was evaluated based on the change in Wrinkle Severity Rating Scale (WSRS) from baseline. Local tolerability was assessed based on subject diary during the first 3 weeks after injection. Adverse events were also evaluated. Results…

medicine.medical_specialtyErythemabusiness.industrySoft tissueDermatologylaw.inventionSurgeryClinical trialRandomized controlled trialTolerabilitylawEdemamedicinemedicine.symptomAdverse effectbusinessWrinkleJournal of Cosmetic Dermatology
researchProduct